Center for Translational Medicine and Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA; Faculty of Medicine, University of Crete, Voutes, Greece.
Center for Translational Medicine and Department of Pharmacology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
J Mol Cell Cardiol. 2019 Feb;127:232-245. doi: 10.1016/j.yjmcc.2018.12.016. Epub 2019 Jan 3.
Sepsis is the overwhelming systemic immune response to infection, which can result in multiple organ dysfunction and septic shock. Myocardial dysfunction during sepsis is associated with advanced disease and significantly increased in-hospital mortality. Our group has shown that energetic failure and excess reactive oxygen species (ROS) generation constitute major components of myocardial dysfunction in sepsis. Because ROS production is central to cellular metabolic health, we tested if the synthetic anti-oxidant lignan secoisolariciresinol diglucoside (SDG; LGM2605) would alleviate septic cardiac dysfunction and investigated the underlying mechanism. Using the cecal ligation and puncture (CLP) mouse model of peritonitis-induced sepsis, we observed impairment of cardiac function beginning at 4 h post-CLP surgery. Treatment of mice with LGM2605 (100 mg/kg body weight, i.p.) 6 h post-CLP surgery reduced cardiac ROS accumulation and restored cardiac function. Assessment of mitochondrial respiration (Seahorse XF) in primary cardiomyocytes obtained from adult C57BL/6 mice that had undergone CLP and treatment with LGM2605 showed restored basal and maximal respiration, as well as preserved oxygen consumption rate (OCR) associated with spare capacity. Further analyses aiming to identify the cellular mechanisms that may account for improved cardiac function showed that LGM2605 restored mitochondria abundance, increased mitochondrial calcium uptake and preserved mitochondrial membrane potential. In addition to protecting against cardiac dysfunction, daily treatment with LGM2605 and antibiotic ertapenem (70 mg/kg) protected against CLP-associated mortality and reversed hypothermia when compared against mice receiving ertapenem and saline. Therefore, treatment of septic mice with LGM2605 emerges as a novel pharmacological approach that reduces cardiac ROS accumulation, protects cardiac mitochondrial function, alleviates cardiac dysfunction, and improves survival.
脓毒症是感染引起的全身性免疫反应过度,可导致多器官功能障碍和感染性休克。脓毒症期间的心肌功能障碍与疾病进展有关,并显著增加住院死亡率。我们的研究小组已经表明,能量衰竭和过量的活性氧(ROS)产生是脓毒症心肌功能障碍的主要组成部分。由于 ROS 产生是细胞代谢健康的核心,我们测试了合成抗氧化剂木脂素 secoisolariciresinol diglucoside(SDG;LGM2605)是否可以缓解脓毒症性心脏功能障碍,并研究了其潜在机制。我们使用盲肠结扎和穿刺(CLP)小鼠模型,观察到腹膜炎诱导的脓毒症术后 4 小时开始出现心脏功能障碍。术后 6 小时给予小鼠 LGM2605(100mg/kg 体重,腹腔注射)治疗可减少心脏 ROS 积累并恢复心脏功能。对接受 CLP 手术并接受 LGM2605 治疗的成年 C57BL/6 小鼠原代心肌细胞的线粒体呼吸( Seahorse XF)进行评估显示,基础和最大呼吸恢复,以及与备用能力相关的耗氧量率(OCR)保持不变。进一步的分析旨在确定可能解释心脏功能改善的细胞机制,表明 LGM2605 恢复了线粒体丰度,增加了线粒体钙摄取并维持了线粒体膜电位。除了预防心脏功能障碍外,与接受恩诺沙星和生理盐水的小鼠相比,每日用 LGM2605 和抗生素厄他培南(70mg/kg)治疗可预防 CLP 相关死亡率并逆转体温过低。因此,用 LGM2605 治疗脓毒症小鼠是一种新的药理学方法,可减少心脏 ROS 积累,保护心脏线粒体功能,缓解心脏功能障碍,并提高生存率。